January 22, 2016

Company Name	3-D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
TEL	+81 3 (3511)3440

Absorbable Hemostat PuraStat®
Product Registration Obtained in Australia

The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company hereby announces that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA).

The group has obtained CE marking for the absorbable hemostat PuraStat® on January 14, 2014. This CE marking can be leveraged by using it as a reference regulatory agency approval in various countries in Asia-Pacific and Latin America. The product can be commercially marketed once approval is obtained in each country.

With this medical device product registration approval, marketing and sales activities in Australia can start.

3DMA had already entered into a partnership agreement with Maquet Australia Pty Ltd ("Maquet", head office located at Level 2, 4 Talavera Road, Macquarie Park, NSW 2133, Australia) for sales and marketing of PuraStat® in Australia during the 2nd quarter of fiscal year 2016. With this TGA approval, 3DMA will start sales through Maquet this quarter.

The impact on the company's earning is minimal at this point. This announcement does not influence the earning forecast of the company at this moment. However, should there be any changes, announcement will be made promptly.